Gan & Lee Pharmaceuticals Co. Ltd (Shanghai: 603087.SH), a China-based manufacturer and distributer of pharmaceutical products, announced on Thursday that it has completed two randomised, multicentre phase three studies that compare biosimilar insulin glargine offered by the company (GL-GLA) to a reference biological product.
Both studies were carried out separately in patients with type 1 (n = 576) and type 2 (n = 567) diabetes mellitus.
The primary objective of the studies that were conducted for 26 weeks was to evaluate the equivalence of treatment-induced immunogenicity between GL-GLA and the reference biologic utilising pre-specified similarity margins. The secondary objectives were to evaluate the equivalence of efficacy and safety. Both studies have indicated that treatment-induced immunogenicity was equivalent. The between-group efficacy estimates were within the pre-specified similarity margins and were found to be equivalent. Safety parameters were comparable between GL-GLA and the reference biologic.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults